Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
Status:
Completed
Trial end date:
2018-06-20
Target enrollment:
Participant gender:
Summary
To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with
LCZ696 in HFrEF patients following stabilization after an ADHF episode.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination